Pathos AI has closed a $237M Series E at a post-money valuation of roughly $3B, with Bristol Myers Squibb leading the round and existing investors filling it out. The New York company says the money scales Foundry, its platform that runs thousands of agents against trial, genomic and specimen data to estimate which drug programs are worth pursuing.
CEO Iker Huerga’s team now holds four clinical-stage oncology assets. The capital is earmarked for a registrational study of JSKN016, an asset the platform surfaced.
Why Pharma paid to lead
The bigger shift is therapeutic. Pathos built its name in cancer; the new money extends it into neurology through a BMS partnership centered first on Alzheimer’s disease. Tempus AI is supplying datasets for that work.
The bet rests on a stubborn statistic. Most compounds that enter human trials never reach patients, and Pathos argues agents reading real-world and molecular evidence can sort the likely winners earlier than human review alone. Agents also weigh how crowded a target already is.
An agent debate with a valuation attached
Clinical AI vendors have spent the year arguing that agentic systems belong in development, not just discovery. Sponsors have been slower to pay for the claim. A large pharma leading, rather than watching, is the strongest signal yet that at least one buyer believes it.
What remains unproven is the endpoint that matters: whether a Foundry-selected asset clears a registrational trial. Pathos now has its shot to answer that.
